cancer research campaign the uk charity has signed a deal with a us pharmaceuticals company to develop a pioneering cancer treatment which could earn the charity as much as pounds 20 m a year the drug called temozolomide is the first effective treatment for glioma a form of brain-tumour cancer research funded research and development of the drug which was originally discovered by aston university in birmingham further clinical trials to establish the drug's effectiveness on other forms of cancer are being set up professor edward newlands the head of cancer medicine at charing cross and westminster medical school and director of the drug's clinical trials said it may prove effective against bone marrow cancer the agreement with schering-plough the largest ever concluded by the charity's wholly-owned technology transfer company is worth an immediate dollars 1.5 m with a further dollars 4 m paid to the charity during development once the drug is launched the charity will receive royalty payments these could be worth up to pounds 20 m a year according to dr sue foden managing director of cancer research campaign technology the charity's technology transfer subsidiary last year the charity's income raised mainly through voluntary contributions was pounds 40.6 m under the agreement the charity will receive about 40 per cent of royalties which are worth between 2 per cent and 8 per cent of sales depending on volume the remaining 60 per cent of royalties will be paid to rhone-poulenc rorer the franco-american company that helped with initial research aston university which discovered the molecule and charing cross and westminster medical school which developed it professor newlands explained that half of glioma patients using the drug had shown clinical benefit and as many as 40 per cent had demonstrated an improvement when examined with brain-scans patients with skin cancer had also shown some improvement he said this was the first time a drug had had a repeatable noteworthy effect on brain tumours the charity said that it hoped schering-plough would be able to use the us food and drug administration's accelerated licensing programme so that the medicine would be on the american market within five years the potential market for temozolomide was difficult to predict because it depended whether it worked against other cancers professor newlands said